OnKure Therapeutics has announced the completion of its merger with Reneo Pharmaceuticals. Subsequent to the merger, the company raised USD 65 million in a private placement, joined by new and existing investors, including Acorn Bioventures, Cormorant Asset Management, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Surveyor Capital, and Vestal Point Capital.
Post-merger, the combined company will operate under the name OnKure. It plans to start trading its shares on the Nasdaq Global Market on October 7, 2024, under the ticker symbol "OKUR." The company will advance its pipeline of candidates targeting PI3Kα mutations, focusing on breast cancer. The early clinical data for its key program, OKI-219, is expected in Q4 2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.